Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The company will present findings on a novel GABAB receptor positive allosteric modulator for chronic cough at the Thirteenth London International Cough Symposium [1] Group 1: Company Overview - Addex Therapeutics is developing a portfolio of allosteric modulators targeting neurological disorders, with lead drug candidate ADX71149 having completed several Phase 2 clinical studies [3] - The second clinical program, dipraglurant, is under evaluation for dyskinesia associated with Parkinson's disease and post-stroke/TBI recovery [3] - Addex has a partnership with Indivior for GABAB PAM programs, advancing multiple drug candidates for substance use disorder and an independent program for chronic cough [3] Group 2: GABAB Receptor and Chronic Cough - GABAB receptors are expressed in airways and the cough neural circuit, and their activation has been clinically validated with baclofen, a selective GABAB agonist [2] - Baclofen's use is limited due to side effects and loss of efficacy, while targeting an allosteric binding site of the GABAB receptor is expected to offer advantages like higher selectivity and better tolerability [2]
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)